3.3800
-0.1400
(-3.98%)
At close: January 10 at 4:00:02 PM EST
3.3500
-0.03
(-0.89%)
After hours: January 10 at 7:52:09 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
31,265.0000
27,250.0000
40,800.0000
33,094.0000
14,750.0000
Operating Income
-31,265.0000
-27,250.0000
-40,800.0000
-33,094.0000
-14,750.0000
Net Non Operating Interest Income Expense
-688.0000
-2,028.0000
-1,590.0000
17.0000
69.0000
Other Income Expense
-990.0000
-537.0000
40.0000
-75.0000
-49.0000
Pretax Income
-32,943.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
Net Income Common Stockholders
-32,943.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
Diluted NI Available to Com Stockholders
-32,943.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
Basic EPS
-1.12
-1.50
-4.00
-4.08
-5.42
Diluted EPS
-1.12
-1.50
-4.00
-4.08
-5.42
Basic Average Shares
28,734.1150
19,827.3540
10,593.0340
8,119.8360
2,718.9090
Diluted Average Shares
28,734.1150
19,827.3540
10,593.0340
8,119.8360
2,718.9090
Total Expenses
31,265.0000
27,250.0000
40,800.0000
33,094.0000
14,750.0000
Net Income from Continuing & Discontinued Operation
-32,943.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
Normalized Income
-31,961.0000
-29,287.0000
-42,350.0000
-33,152.0000
-14,730.0000
Interest Income
2,082.0000
825.0000
199.0000
17.0000
69.0000
Interest Expense
2,770.0000
2,853.0000
1,789.0000
--
--
Net Interest Income
-688.0000
-2,028.0000
-1,590.0000
17.0000
69.0000
EBIT
-30,173.0000
-26,962.0000
-40,561.0000
-33,152.0000
-14,730.0000
EBITDA
-29,945.0000
-26,734.0000
-40,325.0000
-32,902.0000
-14,475.0000
Reconciled Depreciation
228.0000
228.0000
236.0000
250.0000
255.0000
Net Income from Continuing Operation Net Minority Interest
-32,943.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
Total Unusual Items Excluding Goodwill
-982.0000
-528.0000
--
--
--
Total Unusual Items
-982.0000
-528.0000
--
--
--
Normalized EBITDA
-28,963.0000
-26,206.0000
-40,325.0000
-32,902.0000
-14,475.0000
12/31/2020 - 10/12/1995
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SCPH scPharmaceuticals Inc.
3.4000
-0.58%
AKTX Akari Therapeutics, Plc
1.2150
-5.08%
IFRX InflaRx N.V.
2.2300
-4.29%
XBIO Xenetic Biosciences, Inc.
3.8600
-4.22%
LRMR Larimar Therapeutics, Inc.
3.6600
-3.43%
GHRS GH Research PLC
8.57
-4.57%
LENZ LENZ Therapeutics, Inc.
23.21
-11.88%
CNTA Centessa Pharmaceuticals plc
15.64
-2.86%
SLNO Soleno Therapeutics, Inc.
43.11
-3.17%
RNXT RenovoRx, Inc.
1.3300
+0.76%